Moderna promises to research its Omicron-specific booster vaccine for adult patients aged 18 or older.
Moderna Inc has started a mid-stage study that will test an additional dose of COVID-19, a vaccine specifically designed to fight the Omicron coronavirus type, one day after its rival Pfizer Inc (PFE.N) has launched a twin study.
On Wednesday, the company stated that, while the third dose of its coronavirus vaccine raised neutralizing antibodies to the variation in low doses, they diminished after six months since that booster shot was given.
However, neutralizing antibodies were visible in all participants, Moderna stated.
Although studies have shown that Omicron produces a less severe form of COVID-19 than in prior waves, the disease has rapidly become the norm globally, increasing the number of infections and straining healthcare systems.
Pfizer and its associate BioNTech began a clinical study on Tuesday to test the effectiveness of a new vaccine designed explicitly for Omicron. Omicron variant.
Moderna has announced it will investigate its Omicron-specific booster among people aged 18 and over.
It is promising to share findings from the study with health professionals to make a logical decision regarding the most effective booster strategy to fight the coronavirus.
The US Centers for Disease Control and Prevention research studies have proven the third dosage, an mRNA vaccine-like those offered by Pfizer and Moderna, is essential in fighting this Omicron variant.
Some countries have begun providing additional doses of boosters; however, a study conducted in Israel revealed that even though the fourth dose of mRNA vaccine increased antibodies, it did not reach the level needed to stop the Omicron infection.
